Anti‐TNFα (Remicade®) therapy protects dystrophic skeletal muscle from necrosis
Open Access
- 20 February 2004
- journal article
- research article
- Published by Wiley in The FASEB Journal
- Vol. 18 (6), 676-682
- https://doi.org/10.1096/fj.03-1024com
Abstract
No abstract availableKeywords
This publication has 52 references indexed in Scilit:
- The new frontier in muscular dystrophy research: booster genesThe FASEB Journal, 2003
- Pharmacological strategies for muscular dystrophyNature Reviews Drug Discovery, 2003
- Myoblast transplantation: the current status of a potential therapeutic tool for myopathies.Journal of Muscle Research and Cell Motility, 2003
- Immunological hurdles in the path to gene therapy for Duchenne muscular dystrophyExpert Reviews in Molecular Medicine, 2002
- Overexpression of a calpastatin transgene in mdx muscle reduces dystrophic pathologyHuman Molecular Genetics, 2002
- Regenerated mdx mouse skeletal muscle shows differential mRNA expressionJournal of Applied Physiology, 2002
- Overexpression of the cytotoxic T cell GalNAc transferase in skeletal muscle inhibits muscular dystrophy in mdx miceProceedings of the National Academy of Sciences of the United States of America, 2002
- Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx miceThe Journal of cell biology, 2002
- The muscular dystrophiesThe Lancet, 2002
- A chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophin-deficient mdx miceHuman Molecular Genetics, 2002